Biotech

All Articles

Despite ph. 3 miss out on, Alkeus views road in advance for eye illness asset

.Though Alkeus Pharmaceuticals' dental eye illness property failed to considerably reduce geographic...

Kairos goes social along with $6M IPO to money trials of cancer cells medication

.With a trio of biotechs striking the Nasdaq on Friday, it was actually easy to miss out on a smalle...

Vaccine and also Keytruda combo successful in squamous cell carcinoma

.Immune system gate inhibitors are the superheroes of cancer therapy. Medicines like Bristol Myers S...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of substantial leadership hirings, shootings ...

Regeneron's Opdualag opponent reveals 57% action fee

.Regeneron is actually back along with long-lasting follow-up for its LAG-3 prevention and PD-1 inhi...

AstraZeneca posts records on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early examine the efficiency of its own in-house antibody-drug conjuga...

iTeos- GSK's TIGIT celebrity reveals relevant enhancement

.After declaring a phase 3 launch based upon good midstage end results, iTeos and GSK are actually e...

More collective FDA can accelerate uncommon ailment R&ampD: report

.The FDA should be actually more available and also joint to let loose a rise in commendations of un...

Zenas, MBX, Bicara scalp to Nasdaq in hot time for biotech IPOs

.It's an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics a...

Atea's COVID antiviral fails to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has fallen short an additional COVID-19 test, yet the biotech still...